Gilead Sciences’ Harvoni (ledipasvir/sofosbuvir) posted excellent results in curing genotypes 4 and 5 of hepatitis C virus (HCV), including among those with cirrhosis, in a recent small trial. The open-label Phase II study of Harvoni included 44 people with genotype 4 and 41 people with genotype 5. Half of the participants had cirrhosis.

Researchers presented the results of the study at the 50th International Liver Congress in Vienna, Austria.

Ninety-three percent (41 of 44) of those with genotype 4 achieved a sustained virologic response 12 weeks after completing therapy (SVR12, considered a cure), as did 95 percent (39 of 41) of those with genotype 5. The cure rates were similar regardless of whether the participants had cirrhosis.

The most common side effects, reported by 10 percent or more of the participants, were weakness, headache and fatigue.

To read a press release about the study, click here.